Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2026-03-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于使用自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the use of its own funds for cash management. It details the board resolution approving the use of up to 700 million RMB of temporarily idle funds for safe, liquid, and principal-guaranteed investment products. The document includes investment purpose, amount, duration, risk control measures, and the board meeting date approving the proposal. It is a formal disclosure of a financing or capital management activity rather than a financial report or earnings release. The document length is short (1841 characters) and it is an announcement of a corporate financing decision, not a full report or financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2026-03-30 Chinese
2025年年度报告摘要
Annual Report Classification · 98% confidence The document is titled "深圳微芯生物科技股份有限公司2025 年年度报告摘要" which translates to "Shenzhen Microchip Biotechnology Co., Ltd. 2025 Annual Report Summary." It contains detailed financial data for the year 2025, including total assets, net profit, revenue, quarterly financial data, shareholder information, and extensive business and product descriptions. The document references the full annual report and audit report by KPMG with an unqualified opinion. The length is substantial (15,000 characters), and it contains comprehensive financial and operational information typical of an annual report. It is not a brief announcement or a certification letter, but a detailed summary of the annual report itself. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-30 Chinese
2025年度独立董事述职报告（王艳梅）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Shenzhen Microcore Biotechnology Co., Ltd. for the year 2025. It includes the director's background, attendance at board and committee meetings, exercise of duties, communication with shareholders, oversight of audit and internal controls, and evaluation of company governance and financial reporting. The content is a comprehensive narrative of the independent director's work and oversight during the fiscal year, which aligns with a Management Report or detailed governance-related disclosure. It is not a full Annual Report (10-K) or Audit Report (AR), nor is it a brief announcement or certification. The document focuses on board/management information and governance aspects, but since it is specifically an independent director's annual work report, it fits best under Board/Management Information (MANG). The document length (4710 characters) and detailed content confirm it is a substantive report, not a mere announcement or certification.
2026-03-30 Chinese
第三届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 25th meeting of the third board of directors of Shenzhen Microchip Biotechnology Co., Ltd. It includes approvals of the 2025 annual report and its summary, the 2025 board work report, the 2025 general manager work report, internal control evaluation report, ESG report, audit committee reports, independent directors' reports, audit firm evaluation, remuneration plans, fundraising usage reports, financing proposals, and plans for the 2025 annual shareholders meeting. The document is lengthy (7257 characters) and contains substantive content about the board's decisions and reports related to the 2025 fiscal year. It is not merely an announcement of a report publication but includes actual resolutions and summaries of reports. The focus is on board meeting resolutions and management reports related to the annual report and other governance matters. Given the content, this document fits best under Board/Management Information (MANG) as it announces board meeting resolutions and management reports rather than the full annual report itself or just an announcement of report publication. Therefore, the classification is MANG with high confidence.
2026-03-30 Chinese
董事会对独立董事2025年度独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of independent directors for the year 2025. It references regulatory requirements related to independent directors and their independence evaluation. The content focuses on governance and compliance with rules about board members' independence, rather than financial data or shareholder voting results. It is not an annual report, audit report, or earnings release. It is not a notice of voting results or a proxy statement. The document is a governance-related report about board members' independence, which fits best under Governance Information (CGR). The document length is short and it is a standalone report, not an announcement of a report publication or certification letter. Therefore, the classification is CGR with high confidence.
2026-03-30 Chinese
关于深圳微芯生物科技股份有限公司2025年度非经营性资金占用及其他关联资金往来情况的专项说明
Regulatory Filings
2026-03-30 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.